Method for treating inflammation with an
A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.
1. A method for reducing or alleviating inflammation in a subject, the method including the step of administering to the subject a therapeutically effective amount of Ac-TMP-2 protein having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2 and that retains anti-inflammatory activity, to thereby reduce or alleviate the inflammation.
2. The method of claim 1 , wherein the inflammation is associated with, or secondary to, a disease disorder or condition in the subject.
3. The method of claim 2 , wherein the disease, disorder and/or condition is refractory to a baseline therapy.
4. The method of claim 3 , wherein the baseline therapy comprises administration of at least one baseline agent selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDs), aminosalicylates, corticosteroids, immunosuppressants, anti-cytokine/cytokine receptor agents, antibiotics, and combinations thereof.
5. The method of claim 3 , wherein, at least initially, Ac-TMP-2 protein is administered adjunctively with the baseline therapy.
6. The method of claim 3 , wherein, at least initially, Ac-TMP-2 protein is administered adjunctively with the at least one baseline agent, which is administered at less than a full dose.
7. The method of claim 2 , wherein the disease, disorder and/or condition is an immunological disease, disorder and/or condition.
8. The method of claim 7 , wherein the immunological disease, disorder and/or condition is selected from the group consisting of Addison's disease, ankylosing spondylitis, celiac disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal ostomyelitis (CRMO), Crohn's disease, demyelinating neuropathies, glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), insulin-dependent diabetes (type1), juvenile arthritis, Kawasaki syndrome, multiple sclerosis, myasthenia gravis, postmyocardial infarction syndrome, primary biliary cirrhosis, psoriasis, idiopathic pulmonary fibrosis, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus (SLE), thrombocytopenic purpura (TTP), ulcerative colitis, vasculitis, vitiligo, and Wegener's granulomatosis.
9. The method of claim 2 , wherein the disease is a disease of the digestive tract.
10. The method of claim 9 , wherein the disease is chronic gastritis or an inflammatory bowel disease.
11. The method of claim 10 , wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
12. The method of claim 8 , wherein the disease is a disease of the respiratory system.
13. The method of claim 12 , wherein the disease is selected from the group consisting of asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease (COPD).
14. A method for preventing and/or treating an inflammatory bowel disease in a subject, the method including the step of administering to the subject a therapeutically effective amount of Ac-TMP-2 protein having at least 95% identity to the amino acid sequences of SEQ ID NO: 2 and that retains anti-inflammatory activity, to thereby treat the inflammatory bowel disease.
15. The method of claim 14 , wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
16. A method for treating asthma in a subject, the method including the step of administering to the subject a therapeutically effective amount of Ac-TMP-2 protein having at least 95% identity to the amino acid sequences of SEQ ID NO: 2 and that retains anti-inflammatory activity, to thereby treat the asthma.
17. The method of any preceding claim, further including the step of administering to the subject at least one additional agent.
18. The method of claim 17 , wherein the at least one additional agent is selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDs), aminosalicylates, cortico steroids, immunosuppressants, anti-cytokine/cytokine receptor agents, antibiotics, and combinations thereof.
19. A pharmaceutical composition comprising a therapeutically effective amount of:
(a) Ac-TMP-2 protein having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2 and that retains anti-inflammatory activity, together with a pharmaceutically acceptable carrier, diluent or excipient, and
(b) at least one additional agent selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDs), aminosalicylates, corticosteroids, immunosuppressants, anti-cytokine/cytokine receptor agents, antibiotics, and combinations thereof.
20. The method of claim 1 , wherein the Ac-TMP-2 protein comprises the amino acid sequence of SEQ ID NO: 2.
21. The method of claim 14 , wherein the Ac-TMP-2 protein comprises the amino sequence of SEQ ID NO: 2.
22. The method of claim 16 , wherein the Ac-TMP-2 protein comprises the amino sequence of SEQ ID NO: 2.